Search Government Affairs
Learn about policy issues important to medical schools and teaching hospitals, with Executive Vice President Atul Grover, M.D., Ph.D.
Future innovations in health care and prevention require research across a full spectrum of biomedical science, from basic and translational research to implementation science and comparative effectiveness research.
AAMC advocates for funding and appropriate regulation by major federal agencies and organizations supporting this research, including the National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), and the Department of Veterans Affairs (VA).
Ensuring a sustainable research mission is essential to achieve long-term health priorities, develop new therapeutics and preventive measures, focus on patient-centered outcomes, and reduce health disparities.
|Responsible Conduct of Research|
|Research with Animals||Stem Cell Research and Regenerative Medicine|
News and Updates
March 17, 2017
Members of Congress and stakeholders in the health community expressed concern over the fiscal year (FY) 2018 budget blueprint released March 16 by the White House.
March 10, 2017
Senators in two rounds of questions at a March 8 Senate Labor-HHS-Education Appropriations Subcommittee hearing, “Saving Lives Through Medical Research,” praised the research funded by the National Institutes of Health (NIH) and urged a commitment to sustainable increases in NIH funding.
March 3, 2017
President Trump Feb. 24 signed an executive order requiring the head of each federal agency to designate a Regulatory Reform Officer (RRO) to oversee and enforce implementation of the administration’s regulatory reform policies and initiatives.
March 3, 2017
The House Appropriations Labor, Health and Human Services, and Education (LHHS) Subcommittee Mar. 1 held its Member’s Day hearing, in which Members of Congress testified about their priorities for fiscal year (FY) 2018 appropriations under the subcommittee’s jurisdiction.
February 24, 2017
The US Patent and Trademark Office Patent Trial and Appeal Board Feb. 15 ruled that patents on the gene editing technology CRISPR-Cas9 held by the Broad Institute of the Massachusetts Institute of Technology and Harvard University do not overlap or “interfere” with University of California (UC) Berkeley patent claims.